| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2005;46:622.)
© 2005 American Heart Association, Inc.
Original Articles |
From the Departments of Internal Medicine (K.C., J.C., J.L., J.X., D.L., T.S., P.L.H., J.L.M.) and Physiology and Biophysics (J.C., J.L.M.), University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Ark.
Correspondence to J.L. Mehta, MD, PhD, Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, 4301 W Markham St, Slot 532, Little Rock, AR 72205. E-mail MehtaJL{at}uams.edu
The endothelial lectinlike, oxidatively (ox-) modified LDL receptor LOX-1 is a critical player in the pathogenesis of atherosclerosis and myocardial ischemia. Ox-LDL binding of LOX-1 results in the expression of various adhesion molecules, which attract monocytes to endothelial cells, an initial step in atherogenesis. We wished to examine the role of the ox-LDL/LOX-1 signaling pathway in fibroblasts, which naturally express low levels of LOX-1. Rat cardiac fibroblasts were transfected with either cytomegalovirus (CMV)-LOX-1wt (amino acids [aa] 1 to 273) or CMV-LOX-11-261 (an ox-LDLbinding negative mutant, aa 1 to 261) plasmid. Western blots showed that LOX-1 protein expression was increased significantly in cells transfected with CMV-LOX-1wt or CMV-LOX-11-261 plasmid (P<0.01 vs control). Fibroblasts transfected with CMV-LOX-1wt showed ox-LDL binding, whereas fibroblasts without transfection and those transfected with CMV-LOX-11-261 did not bind ox-LDL. Compared with untransfected cells, ox-LDL treatment (50 µg/mL, 24 hours) markedly induced the expression of the leukocyte adhesion molecules intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM)-1 as well as matrix metalloproteinase (MMP)-1 in cells transfected with CMV-LOX-1wt (P<0.05) but not in cells transfected with CMV-LOX-11-261. Concurrently, ox-LDL treatment enhanced the phosphorylation of p38 mitogen-activated protein kinase (MAPK) (P<0.05 vs control) in CMV-LOX-1wttransfected cells. These data suggest that in cardiac fibroblasts, ox-LDL binds to LOX-1 and activates p38 MAPK, followed by the expression of ICAM-1, VCAM-1, and MMP-1. Thus, fibroblasts transform into an endothelial phenotype on transfection with CMV-LOX-1wt and subsequent exposure to ox-LDL. This study provides a useful model system (plasmid-transfected fibroblasts) to study the molecular biology of LOX-1.
Key Words: lipoproteins fibroblasts collagen genetics
This article has been cited by other articles:
![]() |
C. Hu, A. Dandapat, L. Sun, M. R. Marwali, N. Inoue, F. Sugawara, K. Inoue, Y. Kawase, K.-i. Jishage, H. Suzuki, et al. Modulation of Angiotensin II-Mediated Hypertension and Cardiac Remodeling by Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Deletion Hypertension, September 1, 2008; 52(3): 556 - 562. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Frohlich Excitement of Clinical Investigation: New Basic Mechanisms of Action After Drug Introduction Hypertension, September 1, 2008; 52(3): 465 - 466. [Full Text] [PDF] |
||||
![]() |
H. Satoh, E. Kiyota, Y. Terasaki, T. Sawamura, K. Takagi, H. Mizuta, and M. Takeya Expression and Localization of Lectin-like Oxidized Low-density Lipoprotein Receptor-1 (LOX-1) in Murine and Human Placentas J. Histochem. Cytochem., August 1, 2008; 56(8): 773 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hu, A. Dandapat, L. Sun, J. Chen, M. R. Marwali, F. Romeo, T. Sawamura, and J. L. Mehta LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet Cardiovasc Res, July 15, 2008; 79(2): 287 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hu, A. Dandapat, L. Sun, J. A. Khan, Y. Liu, P. L. Hermonat, and J. L. Mehta Regulation of TGF{beta}1-mediated Collagen Formation by LOX-1: Studies Based on Forced Overexpression of TGF{beta}1 in Wild-Type and Lox-1 J. Biol. Chem., April 18, 2008; 283(16): 10226 - 10231. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Dominguez, J. L. Mehta, D. Li, P. Wu, K. J. Kelly, C. S. Packer, C. Temm, E. Goss, L. Cheng, S. Zhang, et al. Anti-LOX-1 therapy in rats with diabetes and dyslipidemia: ablation of renal vascular and epithelial manifestations Am J Physiol Renal Physiol, January 1, 2008; 294(1): F110 - F119. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hu, A. Dandapat, J. Chen, Y. Fujita, N. Inoue, Y. Kawase, K.-i. Jishage, H. Suzuki, T. Sawamura, and J. L. Mehta LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion Cardiovasc Res, November 1, 2007; 76(2): 292 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-P. Hu, A. Dandapat, Y. Liu, P. L. Hermonat, and J. L. Mehta Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by overexpression of TGF-beta1 delivered by AAV in mouse cardiomyocytes Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1833 - H1838. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Mehta, J. Chen, P. L. Hermonat, F. Romeo, and G. Novelli Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders Cardiovasc Res, January 1, 2006; 69(1): 36 - 45. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |